compounded glp 1 risks National Minority Quality Forum Launches “Health Not Hype” Campaign During Obesity Care Week to Warn Patients About of GLP-1 Drugs From Lab to Last Mile:
Description
AFHP has no conflicts of interest to declare
Sex differences in GLP-1 signaling across species
10/10 recommend
Several trials have demonstrated that GLP-1 RAs reduce cardiovascular risk in patients with type 2 diabetes mellitus and ASCVD or high cardiovascular risk and have beneficial effects on cardio-renal outcomes beyond their blood glucose-lowering effects in type 2 diabetes mellitus patients
There are several considerations including but not limited to high cost, a requirement for prior authorization, and denial of coverage [127]
